TDMS Study 96001-06 Pathology Tables
NTP Experiment-Test: 96001-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC STODDARD SOLVENT (TYPE IIC) Date: 09/25/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:09:21
FINAL #1 MICE
Facility: Battelle Northwest
Chemical CAS #: 64742-88-7
Lock Date: 09/25/01
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 96001-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC STODDARD SOLVENT (TYPE IIC) Date: 09/25/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:09:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 550 1100 2200
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 6 11 11 10
Natural Death 8 5 12 6
Survivors
Terminal Sacrifice 36 34 27 34
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (40) (43) (32) (45)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Intestine Large, Rectum (44) (48) (44) (47)
Intestine Large, Cecum (43) (47) (44) (46)
Leiomyosarcoma 1 (2%)
Intestine Small, Duodenum (43) (45) (44) (47)
Carcinoma 1 (2%)
Intestine Small, Jejunum (43) (47) (43) (47)
Carcinoma 1 (2%)
Intestine Small, Ileum (43) (47) (44) (46)
Carcinoma 1 (2%)
Liver (50) (50) (50) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
Hepatocellular Carcinoma 4 (8%) 7 (14%) 4 (8%) 6 (12%)
Hepatocellular Carcinoma, Multiple 2 (4%) 1 (2%)
Hepatocellular Adenoma 9 (18%) 9 (18%) 11 (22%) 11 (22%)
Hepatocellular Adenoma, Multiple 3 (6%) 4 (8%) 7 (14%)
Hepatocholangiocarcinoma 2 (4%)
Hepatocholangiocarcinoma, Multiple 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (4%) 1 (2%) 2 (4%)
Sarcoma, Metastatic, Skin 1 (2%)
Mesentery (4) (15) (21) (11)
Carcinoma, Metastatic, Intestine Small, Ileum 1 (5%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (9%)
Histiocytic Sarcoma 1 (9%)
Sarcoma 1 (7%)
Sarcoma, Metastatic, Skin 2 (10%)
Oral Mucosa (1)
Pharyngeal, Squamous Cell Carcinoma 1 (100%)
Page 2
NTP Experiment-Test: 96001-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC STODDARD SOLVENT (TYPE IIC) Date: 09/25/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:09:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 550 1100 2200
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Pancreas (49) (50) (48) (49)
Carcinoma, Metastatic, Intestine Small, Ileum 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Salivary Glands (50) (49) (49) (50)
Stomach, Forestomach (49) (50) (49) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Squamous Cell Papilloma 1 (2%) 1 (2%)
Stomach, Glandular (47) (49) (47) (47)
Adenoma 1 (2%) 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Carcinoma, Metastatic, Intestine Small, Ileum 1 (2%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (49) (50)
Carcinoma, Metastatic, Intestine Small, Ileum 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Subcapsular, Adenoma 1 (2%) 1 (2%)
Adrenal Medulla (49) (50) (48) (49)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 1 (2%) 1 (2%)
Islets, Pancreatic (49) (50) (48) (48)
Adenoma 1 (2%) 1 (2%)
Pituitary Gland (47) (49) (49) (48)
Pars Distalis, Adenoma 10 (21%) 8 (16%) 10 (20%) 10 (21%)
Pars Distalis, Carcinoma 1 (2%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (50) (49) (47) (48)
Follicular Cell, Adenoma 2 (4%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 96001-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC STODDARD SOLVENT (TYPE IIC) Date: 09/25/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:09:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 550 1100 2200
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (40) (42) (47) (41)
Carcinoma 1 (2%)
Ovary (49) (50) (48) (49)
Carcinoma 1 (2%)
Cystadenoma 1 (2%) 2 (4%) 1 (2%) 1 (2%)
Granulosa Cell Tumor Benign 1 (2%)
Granulosa-Theca Tumor Benign 1 (2%)
Hemangioma 1 (2%) 1 (2%)
Histiocytic Sarcoma 2 (4%) 2 (4%) 1 (2%)
Sarcoma, Metastatic, Skin 2 (4%)
Teratoma Benign 1 (2%)
Uterus (49) (50) (49) (49)
Adenoma 1 (2%)
Carcinoma 1 (2%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Polyp Stromal 2 (4%) 1 (2%)
Sarcoma Stromal 1 (2%)
Sarcoma Stromal, Multiple 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (49) (48) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%) 1 (2%) 1 (2%)
Lymph Node (5) (7) (9) (10)
Lumbar, Hemangiosarcoma, Metastatic, Spleen 1 (10%)
Lumbar, Histiocytic Sarcoma 1 (20%)
Lumbar, Sarcoma Stromal, Metastatic, Uterus 1 (14%)
Renal, Histiocytic Sarcoma 1 (20%) 1 (14%)
Lymph Node, Bronchial (41) (37) (40) (42)
Carcinoma, Metastatic, Intestine Small, Ileum 1 (3%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (3%) 1 (2%)
Histiocytic Sarcoma 1 (3%) 1 (3%) 1 (2%)
Lymph Node, Mandibular (42) (32) (40) (40)
Page 4
NTP Experiment-Test: 96001-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC STODDARD SOLVENT (TYPE IIC) Date: 09/25/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:09:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 550 1100 2200
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Histiocytic Sarcoma 2 (5%) 1 (3%) 1 (3%)
Lymph Node, Mesenteric (47) (49) (47) (50)
Carcinoma, Metastatic, Uterus 1 (2%)
Carcinoma, Metastatic, Intestine Small, Ileum 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%) 1 (2%) 2 (4%)
Sarcoma, Metastatic, Skin 1 (2%)
Lymph Node, Mediastinal (40) (42) (43) (43)
Carcinoma, Metastatic, Intestine Small, Ileum 1 (2%)
Hemangioma 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 2 (5%) 1 (2%) 2 (5%)
Spleen (49) (50) (48) (47)
Hemangiosarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%) 1 (2%)
Thymus (43) (45) (47) (46)
Carcinoma, Metastatic, Intestine Small, Ileum 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (50) (50) (50)
Carcinoma 1 (2%) 1 (2%)
Skin (50) (50) (50) (50)
Basosquamous Tumor Malignant 1 (2%)
Squamous Cell Papilloma 1 (2%)
Sebaceous Gland, Adenoma 1 (2%)
Subcutaneous Tissue, Hemangioma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%) 3 (6%) 2 (4%)
Subcutaneous Tissue, Sarcoma, Multiple 2 (4%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Osteosarcoma 1 (2%)
Skeletal Muscle (1) (1) (1) (2)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (50%)
____________________________________________________________________________________________________________________________________
Page 5
NTP Experiment-Test: 96001-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC STODDARD SOLVENT (TYPE IIC) Date: 09/25/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:09:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 550 1100 2200
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (50) (50) (50) (50)
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 1 (2%) 2 (4%) 3 (6%) 1 (2%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 2 (4%)
Basosquamous Tumor Malignant, Metastatic,
Skin 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Carcinoma, Metastatic, Islets, Pancreatic 1 (2%)
Carcinoma, Metastatic, Intestine Small, Ileum 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (4%) 4 (8%) 1 (2%) 3 (6%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (4%) 1 (2%) 2 (4%)
Pheochromocytoma Malignant, Metastatic,
Adrenal Medulla 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Nose (49) (50) (50) (49)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Histiocytic Sarcoma 1 (2%)
Sarcoma 1 (2%)
Pleura (1) (1)
Carcinoma, Metastatic, Intestine Small, Ileum 1 (100%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (100%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (46) (49) (45) (46)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Sarcoma 1 (2%)
Harderian Gland (49) (49) (49) (49)
Adenoma 4 (8%) 2 (4%) 4 (8%) 3 (6%)
Carcinoma 1 (2%) 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Page 6
NTP Experiment-Test: 96001-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC STODDARD SOLVENT (TYPE IIC) Date: 09/25/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:09:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 550 1100 2200
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM - cont
Bilateral, Adenoma 2 (4%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (49) (49)
Carcinoma, Metastatic, Intestine Small, Ileum 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%) 2 (4%)
Urinary Bladder (48) (50) (49) (48)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 2 (4%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 2 (4%) 2 (4%) 1 (2%) 2 (4%)
Lymphoma Malignant 5 (10%) 9 (18%) 11 (22%) 8 (16%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 7
NTP Experiment-Test: 96001-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC STODDARD SOLVENT (TYPE IIC) Date: 09/25/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:09:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 550 1100 2200
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 39 41 41 39
Total Primary Neoplasms 61 65 62 66
Total Animals with Benign Neoplasms 27 24 30 27
Total Benign Neoplasms 38 32 38 38
Total Animals with Malignant Neoplasms 19 26 23 23
Total Malignant Neoplasms 23 33 24 28
Total Animals with Metastatic Neoplasms 4 8 4 6
Total Metastatic Neoplasm 6 11 21 19
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 8
NTP Experiment-Test: 96001-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC STODDARD SOLVENT (TYPE IIC) Date: 09/25/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:09:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 550 1100 2200
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 7 9 16 13
Natural Death 9 9 6 5
Accidently Killed 1
Survivors
Terminal Sacrifice 34 32 27 32
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Small, Duodenum (46) (41) (46) (47)
Sarcoma, Metastatic, Skin 1 (2%)
Intestine Small, Jejunum (46) (41) (46) (47)
Carcinoma 3 (7%)
Sarcoma, Metastatic, Skin 1 (2%)
Intestine Small, Ileum (45) (41) (46) (47)
Adenoma 1 (2%)
Carcinoma 2 (4%)
Liver (50) (50) (50) (50)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%) 3 (6%)
Hepatoblastoma 1 (2%)
Hepatocellular Carcinoma 10 (20%) 11 (22%) 12 (24%) 9 (18%)
Hepatocellular Carcinoma, Multiple 6 (12%) 4 (8%) 5 (10%) 1 (2%)
Hepatocellular Adenoma 13 (26%) 16 (32%) 14 (28%) 11 (22%)
Hepatocellular Adenoma, Multiple 10 (20%) 12 (24%) 7 (14%) 18 (36%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Ito Cell Tumor Benign 1 (2%)
Sarcoma 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Mesentery (6) (6) (7) (5)
Sarcoma, Metastatic, Skin 1 (17%)
Pancreas (49) (49) (49) (50)
Sarcoma 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Stomach, Forestomach (49) (48) (49) (49)
Sarcoma, Metastatic, Skin 1 (2%)
Squamous Cell Carcinoma 1 (2%)
Page 9
NTP Experiment-Test: 96001-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC STODDARD SOLVENT (TYPE IIC) Date: 09/25/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:09:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 550 1100 2200
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Squamous Cell Papilloma 2 (4%) 1 (2%)
Stomach, Glandular (48) (44) (49) (48)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (49) (50) (49) (50)
Adenoma 1 (2%)
Carcinoma, Metastatic, Parathyroid Gland 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Bilateral, Subcapsular, Adenoma 1 (2%)
Subcapsular, Adenoma 3 (6%) 2 (4%) 1 (2%) 1 (2%)
Subcapsular, Carcinoma 1 (2%)
Adrenal Medulla (48) (49) (49) (50)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Islets, Pancreatic (48) (49) (49) (50)
Adenoma 1 (2%) 1 (2%)
Pituitary Gland (49) (49) (48) (46)
Thyroid Gland (49) (48) (47) (50)
C-Cell, Carcinoma 1 (2%)
Follicular Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (1) (1) (1)
Histiocytic Sarcoma 1 (100%)
Sarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Coagulating Gland (2)
Adenoma 1 (50%)
Epididymis (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Preputial Gland (49) (49) (50) (48)
Page 10
NTP Experiment-Test: 96001-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC STODDARD SOLVENT (TYPE IIC) Date: 09/25/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:09:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 550 1100 2200
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Histiocytic Sarcoma 1 (2%)
Prostate (46) (50) (50) (50)
Seminal Vesicle (48) (46) (50) (48)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Testes (50) (50) (50) (50)
Interstitial Cell, Adenoma 1 (2%) 2 (4%) 2 (4%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (50) (49) (50)
Hemangiosarcoma 1 (2%)
Lymph Node (1) (1) (3)
Pancreatic, Hepatocellular Carcinoma,
Metastatic, Liver 1 (100%)
Lymph Node, Bronchial (38) (32) (28) (28)
Hemangiosarcoma 1 (3%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (4%)
Histiocytic Sarcoma 1 (3%)
Lymph Node, Mandibular (29) (26) (26) (36)
Lymph Node, Mesenteric (48) (46) (48) (48)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Sarcoma 1 (2%)
Lymph Node, Mediastinal (39) (40) (36) (43)
Hemangiosarcoma 1 (3%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (3%) 1 (2%)
Histiocytic Sarcoma 1 (3%)
Sarcoma, Metastatic, Skin 1 (3%)
Spleen (49) (49) (49) (50)
Hemangiosarcoma 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Thymus (41) (39) (40) (42)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (50)
Melanoma Malignant 1 (2%) 1 (2%)
Squamous Cell Papilloma 1 (2%)
Subcutaneous Tissue, Fibrous Histiocytoma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 2 (4%) 1 (2%)
Page 11
NTP Experiment-Test: 96001-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC STODDARD SOLVENT (TYPE IIC) Date: 09/25/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:09:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 550 1100 2200
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - cont
Subcutaneous Tissue, Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (49) (50) (50)
Alveolar/Bronchiolar Adenoma 5 (10%) 2 (4%) 3 (6%) 1 (2%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 5 (10%) 2 (4%) 4 (8%) 5 (10%)
Alveolar/Bronchiolar Carcinoma, Multiple 2 (4%)
Carcinoma, Metastatic, Harderian Gland 1 (2%) 1 (2%)
Carcinoma, Metastatic, Parathyroid Gland 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 6 (12%) 6 (12%) 9 (18%) 3 (6%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (50) (50) (50) (49)
Adenoma 6 (12%) 6 (12%) 5 (10%) 4 (8%)
Carcinoma 4 (8%) 3 (6%) 3 (6%)
Bilateral, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (49) (50)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Page 12
NTP Experiment-Test: 96001-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC STODDARD SOLVENT (TYPE IIC) Date: 09/25/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:09:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 550 1100 2200
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 3 (6%)
Lymphoma Malignant 3 (6%) 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 13
NTP Experiment-Test: 96001-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC STODDARD SOLVENT (TYPE IIC) Date: 09/25/02
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:09:21
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 550 1100 2200
MG/M3 MG/M3 MG/M3
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 42 43 41 41
Total Primary Neoplasms 73 75 68 68
Total Animals with Benign Neoplasms 32 31 30 33
Total Benign Neoplasms 43 44 34 39
Total Animals with Malignant Neoplasms 23 23 25 23
Total Malignant Neoplasms 30 31 34 29
Total Animals with Metastatic Neoplasms 6 7 10 5
Total Metastatic Neoplasm 16 7 14 8
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 14
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------